

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT

COMMENCEMENT OF PHASE III CLINICAL TRIAL FOR LYOPHILIZED HUMAN RABIES VACCINE (HUMAN DIPLOID CELL)

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Group has recently initiated Phase III clinical trials of the Group’s Lyophilized Human Rabies Vaccine (Human Diploid Cell). Developing this candidate under three immunization regimens, we obtained Investigational New Drug approval from the National Medical Products Administration of the People’s Republic of China for the Essen (five doses) regimen in November 2022 and approval of our supplemental clinical trial application for the Zagreb (four doses) and simplified four-dose regimens in April 2023. We completed a Phase I clinical trial of the candidate in October 2024.

Rabies, a serious viral disease caused by the rabies virus, could develop severe symptoms such as confusion and progressive paralysis. It can be prevented with proper vaccination immediately after exposure to the virus but is almost always fatal once symptoms show. Recommended by the WHO, rabies vaccines developed based on human diploid cells stand as the “gold standard”, showcasing strong safety profiles. Our rabies vaccine candidate demonstrated a promising safety profile in its completed Phase I clinical trial.

About Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

This announcement is published on a voluntary basis by the Company. There is no assurance that the Group will be able to ultimately develop and market its Lyophilized Human Rabies Vaccine (Human Diploid Cell). **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of our Board and general manager

Hong Kong, December 8, 2025

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.